These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 32820478)

  • 21. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19.
    Godoy LC; Goligher EC; Lawler PR; Slutsky AS; Zarychanski R
    CMAJ; 2020 Oct; 192(40):E1156-E1161. PubMed ID: 32816822
    [No Abstract]   [Full Text] [Related]  

  • 22. Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy.
    Ornelas-Ricardo D; Jaloma-Cruz AR
    Tohoku J Exp Med; 2020 Aug; 251(4):327-336. PubMed ID: 32788506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part I.
    Favaloro EJ; Lippi G
    Semin Thromb Hemost; 2020 Oct; 46(7):757-762. PubMed ID: 33080660
    [No Abstract]   [Full Text] [Related]  

  • 24. Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease.
    Lozano R; Franco ME
    Med Clin (Barc); 2020 Nov; 155(9):409-410. PubMed ID: 32883507
    [No Abstract]   [Full Text] [Related]  

  • 25. Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.
    Nauka PC; Oran E; Chekuri S
    Thromb Res; 2020 Aug; 192():27-28. PubMed ID: 32419710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 and venous thromboembolism: current insights and prophylactic strategies.
    Ambrosino P; Di Minno A; Maniscalco M; Di Minno MND
    Ann Med; 2020 Sep; 52(6):239-242. PubMed ID: 32619360
    [No Abstract]   [Full Text] [Related]  

  • 27. COVID-19 and its implications for thrombosis and anticoagulation.
    Connors JM; Levy JH
    Blood; 2020 Jun; 135(23):2033-2040. PubMed ID: 32339221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications.
    Haimei MA
    Clin Appl Thromb Hemost; 2020; 26():1076029620944497. PubMed ID: 32722927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematological findings and complications of COVID-19.
    Terpos E; Ntanasis-Stathopoulos I; Elalamy I; Kastritis E; Sergentanis TN; Politou M; Psaltopoulou T; Gerotziafas G; Dimopoulos MA
    Am J Hematol; 2020 Jul; 95(7):834-847. PubMed ID: 32282949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19.
    Frydman GH; Boyer EW; Nazarian RM; Van Cott EM; Piazza G
    Clin Appl Thromb Hemost; 2020; 26():1076029620943671. PubMed ID: 32702995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection.
    Pooni RS
    Clin Med (Lond); 2020 Jul; 20(4):e59. PubMed ID: 32675158
    [No Abstract]   [Full Text] [Related]  

  • 32. Incidence of venous thromboembolism in hospitalized patients with COVID-19.
    Middeldorp S; Coppens M; van Haaps TF; Foppen M; Vlaar AP; Müller MCA; Bouman CCS; Beenen LFM; Kootte RS; Heijmans J; Smits LP; Bonta PI; van Es N
    J Thromb Haemost; 2020 Aug; 18(8):1995-2002. PubMed ID: 32369666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of the thrombotic risk associated with COVID-19: what is the role of the hemostasis laboratory?].
    Hardy M; Douxfils J; Dogné JM; Lessire S; Chatelain B; Testa S; Gouin-Thibault I; Gruel Y; Lecompte T; Mullier F
    Ann Biol Clin (Paris); 2020 Oct; 78(5):471-481. PubMed ID: 33026344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-arterial thrombosis associated with COVID-19.
    Hamilton KV; Hussey KK
    J Vasc Surg; 2020 Aug; 72(2):757-758. PubMed ID: 32425325
    [No Abstract]   [Full Text] [Related]  

  • 35. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.
    Beyazit F; Beyazit Y; Tanoglu A; Haznedaroglu IC
    Med Hypotheses; 2020 Oct; 143():110150. PubMed ID: 32763660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives on Platelet Heterogeneity and Host Immune Response in Coronavirus Disease 2019 (COVID-19).
    Parra-Izquierdo I; Aslan JE
    Semin Thromb Hemost; 2020 Oct; 46(7):826-830. PubMed ID: 32882716
    [No Abstract]   [Full Text] [Related]  

  • 37. Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines.
    Porfidia A; Pola R
    J Thromb Thrombolysis; 2020 Jul; 50(1):68-71. PubMed ID: 32367471
    [No Abstract]   [Full Text] [Related]  

  • 38. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19.
    Wang T; Chen R; Liu C; Liang W; Guan W; Tang R; Tang C; Zhang N; Zhong N; Li S
    Lancet Haematol; 2020 May; 7(5):e362-e363. PubMed ID: 32278361
    [No Abstract]   [Full Text] [Related]  

  • 39. Correlation of indirect markers of hypercoagulability with thromboelastography in severe coronavirus 2019.
    Hightower S; Ellis H; Collen J; Ellis J; Grasso I; Roswarski J; Cap AP; Chung K; Prescher L; Kavanaugh M; Brown T; Nau M; Clark P
    Thromb Res; 2020 Nov; 195():69-71. PubMed ID: 32659463
    [No Abstract]   [Full Text] [Related]  

  • 40. SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection.
    Llau JV; Ferrandis R; Sierra P; Hidalgo F; Cassinello C; Gómez-Luque A; Quintana M; Amezaga R; Gero M; Serrano A; Marcos P
    Rev Esp Anestesiol Reanim (Engl Ed); 2020; 67(7):391-399. PubMed ID: 32591185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.